In brief: GTG, Resonance Health, Sirtex
07 July, 2005 by Ruth BeranGenetic Technologies (ASX:GTG) has settled all of its disputes with the Auckland District Health Board, as the representative of all the New Zealand district health boards plus the New Zealand Blood Service.
New centre to look at approaches to imaging proteins
07 July, 2005 by Helen SchullerA new Centre of Excellence in Coherent X-Ray Science will be developed with an AUD$9 million ARC grant over five years, involving Australian and overseas universities and other organisations.
Big names on grant winners list
06 July, 2005 by Iain ScottSome of the biggest names in Australian science are among the big winners of more than AUD$100 million in National Health and Medical Research Council grants, announced on Wednesday.
Vet Biotech gets green light for horse stem cell therapy
06 July, 2005 by Helen SchullerAustralian animal health company, Vet Biotechnology, has been given the green light to perform equine supply stem cell therapies for tendon and ligament injuries in Australia.
Cryptome, NTRI to team up on brain trauma drugs
06 July, 2005 by Ruth BeranMelbourne-based Cryptome Pharmaceuticals (ASX:CRP) and the National Trauma Research Institute (NTRI), at the Alfred Hospital, have signed an agreement that will accelerate Cryptome's drug discovery platform in neuroinflammation.
Tissue Therapies claims success in diabetic ulcer study
06 July, 2005 by Helen SchullerA new lab study has shown that Brisbane-based Tissue Therapies' (ASX:TIS) VitroGro technology could stimulate the growth of human skin cells, offering hope for a new treatment for diabetic ulcers, the company said.
NeuroDiscovery to acquire UK firm, list on ASX
05 July, 2005 by Helen SchullerNeuroDiscovery, a Perth-based neurology-focused biotech company, has lodged an IPO prospectus with ASIC to raise funds and acquire 100 per cent of NeuroSolutions, a UK-based service provider and drug discovery company.
Probiotec relocates to Victoria
05 July, 2005 by Helen SchullerProbiotec, which bought Agenix' Milton Pharmaceuticals division earlier this year, has relocated from Brisbane to Victoria.
Mesoblast to establish ADR program
05 July, 2005 by Ruth BeranAdult stem cell company Mesoblast (ASX:MSV), which listed on the ASX six months ago, has appointed the Bank of New York to establish and maintain a Level 1 American Depositary Receipt (ADR) program.
Bone Medical completes Phase I Perthoxal osteoporosis trial
04 July, 2005 by Ruth BeranBone Medical (ASX:BNE) has completed a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal under development for the treatment of osteoporosis.
Novogen bowel disease drug set to enter Phase I trial
04 July, 2005 by Ruth BeranBiopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 is set to enter Phase I trials at the Gold Coast Hospital.
CogState sales topped $1m in 2004-05
04 July, 2005 by Ruth BeranMelbourne-based neurodiagnostic specialist CogState (ASX:CGS) says its sales exceeded AUD$1 million in sales for the 2004-05 fiscal year, up 420 per cent on the previous year, largely through sales to major pharmaceutical companies and research institutions.
In brief: Rockeby, GTG, PharmAust, Mimotopes, Solbec
04 July, 2005 by Ruth BeranRockeby Biomed (ASX:RBY) has lodged a prospectus to raise AUD$1.78 million through a non-renounceable one-for-one share rights issue. The issue price for each share is $0.01 and the company expects the capital to see it through to the end of financial year 2006.
BioProspect cops Euro setback
01 July, 2005 by Graeme O'NeillBrisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.
Apollo Life Sciences lists at premium
01 July, 2005 by Ruth BeranSydney-based biopharmaceutical Apollo Life Sciences (ASX:AOP) has made a stellar debut on the ASX, at a 54 per cent premium to its offer price.
